OBJECTIVE: To determine maternal and perinatal outcome in women with severe preeclampsia at <26 weeks according to gestational age at the onset of expectant management and the presence of severe fetal growth restriction (<5th percentile). STUDY DESIGN: Fifty-one patients (53 fetuses; 2 twins) were retrospectively studied. RESULTS: Median prolongation was 7 days (2-55). Maternal morbidity rate was 43%. Perinatal survival rate was 42%. Severe fetal growth restriction complicated 17 fetuses (33%). There were no perinatal survivors in those managed at <24 weeks (n = 12). For those at 24-24(6/7) and 25-25(6/7) weeks, the perinatal survival rates were 50% and 57%, respectively, and in the presence of severe fetal growth restriction 0% and 30%, respectively. CONCLUSION: Perinatal outcome in severe preeclampsia in the midtrimester is dependent on gestational age and/or the presence of severe fetal growth restriction. Given the high maternal morbidity and the extremely low perinatal survival rates, we do not recommend expectant management before 24 weeks and/or in those with severe fetal growth restriction at any gestational age <26 weeks.
OBJECTIVE: To determine maternal and perinatal outcome in women with severe preeclampsia at <26 weeks according to gestational age at the onset of expectant management and the presence of severe fetal growth restriction (<5th percentile). STUDY DESIGN: Fifty-one patients (53 fetuses; 2 twins) were retrospectively studied. RESULTS: Median prolongation was 7 days (2-55). Maternal morbidity rate was 43%. Perinatal survival rate was 42%. Severe fetal growth restriction complicated 17 fetuses (33%). There were no perinatal survivors in those managed at <24 weeks (n = 12). For those at 24-24(6/7) and 25-25(6/7) weeks, the perinatal survival rates were 50% and 57%, respectively, and in the presence of severe fetal growth restriction 0% and 30%, respectively. CONCLUSION: Perinatal outcome in severe preeclampsia in the midtrimester is dependent on gestational age and/or the presence of severe fetal growth restriction. Given the high maternal morbidity and the extremely low perinatal survival rates, we do not recommend expectant management before 24 weeks and/or in those with severe fetal growth restriction at any gestational age <26 weeks.
Authors: Piya Chaemsaithong; Roberto Romero; Adi L Tarca; Steven J Korzeniewski; Alyse G Schwartz; Jezid Miranda; Ahmed I Ahmed; Zhong Dong; Sonia S Hassan; Lami Yeo; Tinnakorn Tinnakorn Journal: J Matern Fetal Neonatal Med Date: 2014-09-29
Authors: Kartik K Venkatesh; Robert A Strauss; Daniel J Westreich; John M Thorp; David M Stamilio; Katherine L Grantz Journal: Pregnancy Hypertens Date: 2020-03-10 Impact factor: 2.899
Authors: Edailna Maria de Melo Dantas; Flávio Venicio Marinho Pereira; José Wilton Queiroz; Diogo Luis de Melo Dantas; Gloria Regina Gois Monteiro; Priya Duggal; Maria de Fatima Azevedo; Selma Maria Bezerra Jeronimo; Ana Cristina Pinheiro Fernandes Araújo Journal: BMC Pregnancy Childbirth Date: 2013-08-08 Impact factor: 3.007
Authors: Leonoor van Eerden; Christianne J M de Groot; Godelieve C M L Page-Christiaens; Eva Pajkrt; Gerda G Zeeman; Antoinette C Bolte Journal: AJP Rep Date: 2018-11-01
Authors: Mariana A Carvalho; Lina Bejjani; Rossana P V Francisco; Elizabeth G Patino; Alexandre Vivanti; Fernanda S Batista; Marcelo Zugaib; Frédéric J Mercier; Lisandra S Bernardes; Alexandra Benachi Journal: PLoS One Date: 2021-02-03 Impact factor: 3.240
Authors: Ignacio Herraiz; Elisa Simón; Paula Isabel Gómez-Arriaga; José Manuel Martínez-Moratalla; Antonio García-Burguillo; Elena Ana López Jiménez; Alberto Galindo Journal: Int J Mol Sci Date: 2015-08-13 Impact factor: 5.923